US stock futures dip as Trump’s firing of Cook sparks Fed independence fears
Ryan Khouri, CEO of CTT Pharmaceutical (TADAWUL:2070) Holdings, Inc. (OTC:CTTH), has acquired 5,400 shares of the company, according to a recent SEC filing. The shares were purchased at $0.06 each, totaling $324. The transaction comes as CTTH shows strong momentum, with InvestingPro data revealing a remarkable 143% return over the past year. Following this transaction, Khouri’s total direct ownership in the company stands at 6,574,906 shares. This purchase marks a continued investment by the CEO in the company’s future, which InvestingPro analysis rates with a "GOOD" financial health score. The company, currently valued at $3.39 million, maintains strong liquidity with assets exceeding short-term obligations. For more detailed insights and additional ProTips on CTTH’s financial health, visit InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.